Precision medicine company Renalytix plc (LSE: RENX, OTCQB: RNLXY) on Wednesday announced new clinical data demonstrating the positive impact of its KidneyIntelX test on prescribing patterns for sodium-glucose cotransporter 2 inhibitors (SGLT2i). Findings were presented at the National Kidney Foundation Spring Clinical Meetings held in Boston, Massachusetts, from 10 to 13 April 2025.

The late-breaking study, led by Dr Joji Tokita of the Icahn School of Medicine at Mount Sinai, assessed real-world prescribing behaviour within the same health system. Results showed that patients tested with KidneyIntelX received significantly more targeted SGLT2i prescriptions based on their risk profile for diabetic kidney disease progression, with the greatest increases observed in moderate and high-risk groups. In contrast, the control group - who were eligible but not tested - showed less optimised treatment allocation, particularly among high-risk individuals.

Data also indicated that low-risk patients identified by KidneyIntelX did not significantly benefit from SGLT2i for kidney protection, reinforcing the value of risk stratification in guiding clinical decisions.

KidneyIntelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage chronic kidney disease risk assessment. Developed in collaboration with Mount Sinai and deployed across several large US health systems, the test has demonstrated real-world effectiveness in enhancing diagnosis, risk evaluation and treatment decisions. Medicare reimburses USD950 per test.

With over 15,000 patients tested to date, KidneyIntelX has built a robust evidence base supporting its clinical and economic value. The test is now integrated into international chronic kidney disease guidelines (KDIGO).